Os therapies provides ost-her2 recurrent, fully resected, pulmonary metastatic osteosarcoma program update following fda end of phase 2 meeting

Company on track to begin submission of a rolling biologics licensing application (bla) request for ost-her2 to u.s. food & drug administration in september 2025 new york, new york--(newsfile corp. - september 2, 2025) - os therapies inc. (nyse american: ostx) ("os therapies" or "the company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today provided stakeholders with a detailed update regarding the company's ost-her2 recurrent, fully resected, pulmonary metastatic osteosarcoma program (the "metastatic osteosarcoma program") following a highly productive end of phase 2 meeting with the us food & drug administration ("fda"). the company remains on track to begin rolling submission of a biologics licensing application ("bla") request to fda for the metastatic osteosarcoma program in september 2025.
OST Ratings Summary
OST Quant Ranking